Pravastatin Improves Glucose Regulation and Biocompatibility of Agarose Encapsulated Porcine Islets following Transplantation into Pancreatectomized Dogs

Table 2

Histopathology scoring.

Tissue		Nonpravastatin Control Animals	Pravastatin-; treated animals
Heart	Incidence	1/3 (33%)	1/3 (33%)
	Severity	0.3	0.3
Lung	Incidence	2/3 (67%)	1/3 (33%)
	Severity	1.0	0.3
Diaphragm	Incidence	3/3 (100%)	3/3 (100%)
	Severity	2.3	3.0
Liver	Incidence	2/3 (67%)	1/3 (33%)
	Severity	0.7	0.7
Kidney	Incidence	3/3 (100%)	1/3 (33%)
	Severity	1.7	0.7
Spleen	Incidence	3/3 (100%)	3/3 (100%)
	Severity	2.0	1.7
Adrenal Glands	Incidence	2/3 (67%)	2/3 (67%)
	Severity	0.7	0.7
Stomach	Incidence	3/3 (100%)	2/3 (67%)
	Severity	2.7	1.3
Duodenum	Incidence	3/3 (100%)	3/3 (100%)
	Severity	2.7	2.7
Jejunum	Incidence	3/3 (100%)	2/3 (67%)
	Severity	2.0	1.3
Ileum	Incidence	3/3 (100%)	3/3 (100%)
	Severity	2.7	2.3
Mesentery	Incidence	3/3 (100%)	1/3 (33%)
	Severity	1.3	0.7
Mesenteric Lymph Node	Incidence	2/3 (67%)	1/3 (33%)
	Severity	1.0	0.3
Abdominal Wall	Incidence	2/3 (67%)	3/3 (100%)
	Severity	1.3	2.3
Total	Incidence	35/42 (83.3%)	27/42 (64.3%)
	Severity	22.7	18.3

Severity by tissue: mean as determined by dividing sum of severity grades for each animal by number of animals in each group (3). Severity grades were 0–4 for normal, minimal, mild, moderate, and marked, respectively.
Total incidence: sum of incidence for each tissue in relation to total tissues scored.
Total severity: sum of mean severity for each tissue.